Prestige Consumer Healthcare (NYSE:PBH) Raised to “Buy” at StockNews.com

Prestige Consumer Healthcare (NYSE:PBHGet Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

A number of other research analysts have also weighed in on PBH. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a research note on Monday, December 9th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Finally, DA Davidson reaffirmed a “buy” rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and a consensus price target of $85.25.

Read Our Latest Stock Analysis on Prestige Consumer Healthcare

Prestige Consumer Healthcare Stock Up 0.1 %

Prestige Consumer Healthcare stock opened at $76.79 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The stock has a market capitalization of $3.79 billion, a PE ratio of 18.68, a price-to-earnings-growth ratio of 2.17 and a beta of 0.51. The business has a 50 day simple moving average of $80.08 and a 200-day simple moving average of $74.88. Prestige Consumer Healthcare has a 12 month low of $60.00 and a 12 month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBHGet Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. The company had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm’s revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.07 EPS. On average, analysts anticipate that Prestige Consumer Healthcare will post 4.46 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Mary Beth Fritz sold 9,885 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total value of $810,273.45. Following the transaction, the senior vice president now directly owns 18,835 shares in the company, valued at approximately $1,543,904.95. This represents a 34.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares of the company’s stock, valued at $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock valued at $3,187,300 in the last ninety days. 1.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several large investors have recently modified their holdings of PBH. Boston Trust Walden Corp acquired a new position in Prestige Consumer Healthcare in the third quarter valued at about $41,785,000. Allspring Global Investments Holdings LLC boosted its stake in Prestige Consumer Healthcare by 19.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock worth $113,570,000 after buying an additional 255,045 shares during the period. Wellington Management Group LLP purchased a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter valued at approximately $6,342,000. Millennium Management LLC raised its stake in shares of Prestige Consumer Healthcare by 565.1% in the 2nd quarter. Millennium Management LLC now owns 101,218 shares of the company’s stock valued at $6,969,000 after acquiring an additional 86,000 shares during the period. Finally, Barclays PLC boosted its position in shares of Prestige Consumer Healthcare by 346.3% during the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock worth $6,665,000 after purchasing an additional 71,730 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

(Get Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Featured Articles

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.